Pausing for Halftime: A Stratified Analysis of Epidemiological Characteristics and Outcomes in CMV-Seropositive Allogeneic HSCT Recipients with Cscmvi before and after Day 100

Key Points

• CMV-seropositive allogeneic HSCT recipients after Day 100 show differing outcomes.
• Reciprocal analysis reveals significant variations in epidemiological characteristics, affecting patient care.
• Assessment indicates the importance of stratification in managing outcomes in transplant recipients.
• Insights may influence treatment strategies but require validation across larger cohorts.